Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: Brander who wrote (685)	5/12/1998 11:47:00 PM
From: James Perry	Read Replies (2) \| Respond to of 834

Gee, what's with all the kicking and hitting? Doesn't anyone read this thread? I mean, really read it? I see that Novastan was only tested on about 20 people, a small test group being thought adequate for a fast track approval since the drug has long been used in other countries without adverse affect. The FDA does not accept "other country" history; they require adequate testing. They are trying to fast track needed drugs - but Hoecht had gotten an approval of their drug, and while the person who discussed it on this thread gave it sour apples, the drug was nevertheless approved, and must be considered as lessening the "emergency" type need for a drug such as Novastan. Under those circumstances, if any one of those 20 test subjects was anything less than absolutely perfect, I think that what we are seeing is a rather expectable result. At least with more testing to some unknown extent the drug undoubtedly will be approved. And the only thing a reasonable investor can do is to be calm, be patient, and be standing in line to buy more at these fire sale prices. Because they will go back up.